US20030220365A1 - Cell adhesion-inhibiting antiinflammatory compounds - Google Patents
Cell adhesion-inhibiting antiinflammatory compounds Download PDFInfo
- Publication number
- US20030220365A1 US20030220365A1 US10/387,317 US38731703A US2003220365A1 US 20030220365 A1 US20030220365 A1 US 20030220365A1 US 38731703 A US38731703 A US 38731703A US 2003220365 A1 US2003220365 A1 US 2003220365A1
- Authority
- US
- United States
- Prior art keywords
- thieno
- pyridine
- carboxamide
- chlorophenoxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 **CC1=C2C(=C([3*])F([2*])=C1[1*])c([5*])c(C*B)[y]2[4*] Chemical compound **CC1=C2C(=C([3*])F([2*])=C1[1*])c([5*])c(C*B)[y]2[4*] 0.000 description 34
- PACHBDDPJZXFJB-UHFFFAOYSA-N C.C.CC(=S)NN.CC(=S)NNC(=O)C1=CC2=C(C)C=NC=C2S1.CC1=C2C=C(C(=O)O)SC2=CN=C1.CC1=NN=C(C2=CC3=C(C)C=NC=C3S2)S1.CS(=O)(=O)O Chemical compound C.C.CC(=S)NN.CC(=S)NNC(=O)C1=CC2=C(C)C=NC=C2S1.CC1=C2C=C(C(=O)O)SC2=CN=C1.CC1=NN=C(C2=CC3=C(C)C=NC=C3S2)S1.CS(=O)(=O)O PACHBDDPJZXFJB-UHFFFAOYSA-N 0.000 description 2
- MAXIIRWYZMPGSE-UHFFFAOYSA-N *.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3=CC=CS3)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1 Chemical compound *.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.*.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3=CC=CS3)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1 MAXIIRWYZMPGSE-UHFFFAOYSA-N 0.000 description 1
- QWLMNXLFAZQCQH-MNYXATJNSA-N *.CC(=O)C1=CSC(C2=CC3=C(C=NC=C3C)S2)=N1.CC1=CN=CC2=C1C=C(C(N)=S)S2.CC1=CN=CC2=C1C=C(C1=NC(C(N)=O)=CS1)S2.CC1=CN=CC2=C1C=C(C1=NC(N)=CS1)S2.CC1=CN=CC2=C1C=C(C1=NC(NC(=O)OC(C)(C)C)=CS1)S2.ClCCl.N.[3H]F Chemical compound *.CC(=O)C1=CSC(C2=CC3=C(C=NC=C3C)S2)=N1.CC1=CN=CC2=C1C=C(C(N)=S)S2.CC1=CN=CC2=C1C=C(C1=NC(C(N)=O)=CS1)S2.CC1=CN=CC2=C1C=C(C1=NC(N)=CS1)S2.CC1=CN=CC2=C1C=C(C1=NC(NC(=O)OC(C)(C)C)=CS1)S2.ClCCl.N.[3H]F QWLMNXLFAZQCQH-MNYXATJNSA-N 0.000 description 1
- AWIKNPSDGFLQTK-UHFFFAOYSA-N B.CCCOCCOCC.CCOCCOCCOCC(F)(F)C1=CC=C(OC2=CN=CC3=C2C=C(C(=O)NC)S3)C=C1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(F)(F)C(=O)O)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(F)(F)C(C)=O)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1.CO.[NaH] Chemical compound B.CCCOCCOCC.CCOCCOCCOCC(F)(F)C1=CC=C(OC2=CN=CC3=C2C=C(C(=O)NC)S3)C=C1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(F)(F)C(=O)O)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(F)(F)C(C)=O)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1.CO.[NaH] AWIKNPSDGFLQTK-UHFFFAOYSA-N 0.000 description 1
- MDYHVIHDMPIUIN-UHFFFAOYSA-N BC(=O)NC1=CC=C(OC2=CN=CC3=C2C=C(C(=O)OC)S3)C=C1.BC(=O)NC1=CC=C(OC2=CN=CC3=C2C=C(C(N)=O)S3)C=C1.CB(O)NC1=CC=C(O)C=C1.CB(O)NC1=CC=C(OC2=C(C=O)C(Cl)=CN=C2)C=C1.COC(=O)CS.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(N)C=C2)S1.O=C(O)C(F)(F)F.O=CC1=C(Cl)C=NC=C1Cl Chemical compound BC(=O)NC1=CC=C(OC2=CN=CC3=C2C=C(C(=O)OC)S3)C=C1.BC(=O)NC1=CC=C(OC2=CN=CC3=C2C=C(C(N)=O)S3)C=C1.CB(O)NC1=CC=C(O)C=C1.CB(O)NC1=CC=C(OC2=C(C=O)C(Cl)=CN=C2)C=C1.COC(=O)CS.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(N)C=C2)S1.O=C(O)C(F)(F)F.O=CC1=C(Cl)C=NC=C1Cl MDYHVIHDMPIUIN-UHFFFAOYSA-N 0.000 description 1
- BGHBYCBJPLVVBR-UHFFFAOYSA-N C.C.C.C.C.CC1=NC=CC2=C1C=C(C#N)S2.CC1=NC=CC2=C1C=C(C(N)=O)S2.N#CC1=CC2=C(C=CN=C2=Cl)S1.N#CC1=CC2=C(C=CNC2=O)S1.O=C1NC=CC2=C1C=C(Br)S2.O=P(Cl)(Cl)Cl Chemical compound C.C.C.C.C.CC1=NC=CC2=C1C=C(C#N)S2.CC1=NC=CC2=C1C=C(C(N)=O)S2.N#CC1=CC2=C(C=CN=C2=Cl)S1.N#CC1=CC2=C(C=CNC2=O)S1.O=C1NC=CC2=C1C=C(Br)S2.O=P(Cl)(Cl)Cl BGHBYCBJPLVVBR-UHFFFAOYSA-N 0.000 description 1
- UEKFHVKEQPMFCT-UHFFFAOYSA-N C.C.C.C.CC(C)(N)CO.CC1(C)COC(C2=C(C=O)SC=C2)=N1.CC1(C)COC(C2=CSC=C2)=N1.CC1=NN=CC2=C1C=C(C(=O)O)S2.CC1=NN=CC2=C1C=C(C(N)=O)S2.CC1=NN=CC2=C1C=CS2.CN.Cl.ClC1=NN=CC2=C1C=CS2.N.O=C(O)C1=CSC=C1.O=C=O.O=P(Cl)(Cl)Cl.O=S(Cl)Cl.OC1=NN=CC2=C1C=CS2.[Li]CCCC.[Li]CCCC Chemical compound C.C.C.C.CC(C)(N)CO.CC1(C)COC(C2=C(C=O)SC=C2)=N1.CC1(C)COC(C2=CSC=C2)=N1.CC1=NN=CC2=C1C=C(C(=O)O)S2.CC1=NN=CC2=C1C=C(C(N)=O)S2.CC1=NN=CC2=C1C=CS2.CN.Cl.ClC1=NN=CC2=C1C=CS2.N.O=C(O)C1=CSC=C1.O=C=O.O=P(Cl)(Cl)Cl.O=S(Cl)Cl.OC1=NN=CC2=C1C=CS2.[Li]CCCC.[Li]CCCC UEKFHVKEQPMFCT-UHFFFAOYSA-N 0.000 description 1
- XTKONWQNIKCOHA-UHFFFAOYSA-N C.C.C.C1CCOC1.C=CC1=CC2=C(C)C=NC=C2S1.CC1=C2C=C(C(O)CO)SC2=CN=C1.CC1=C2C=C(CO)SC2=CN=C1.COC(=O)C1=CC2=C(C)C=NC=C2S1.CP(Br)(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.O=[Os](=O)(=O)=O.[H]C(=O)C1=CC2=C(C)C=NC=C2S1.[O] Chemical compound C.C.C.C1CCOC1.C=CC1=CC2=C(C)C=NC=C2S1.CC1=C2C=C(C(O)CO)SC2=CN=C1.CC1=C2C=C(CO)SC2=CN=C1.COC(=O)C1=CC2=C(C)C=NC=C2S1.CP(Br)(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.O=[Os](=O)(=O)=O.[H]C(=O)C1=CC2=C(C)C=NC=C2S1.[O] XTKONWQNIKCOHA-UHFFFAOYSA-N 0.000 description 1
- IWMYJQQMONSNAF-UHFFFAOYSA-N C.C.C.CC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(Cl)C=C2)O1.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(Cl)C=C2)O1.NC(=S)C1=CC2=C(C=NC=C2OC2=CC=C(Cl)C=C2)O1.OC1=CC=C(Cl)C=C1 Chemical compound C.C.C.CC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(Cl)C=C2)O1.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(Cl)C=C2)O1.NC(=S)C1=CC2=C(C=NC=C2OC2=CC=C(Cl)C=C2)O1.OC1=CC=C(Cl)C=C1 IWMYJQQMONSNAF-UHFFFAOYSA-N 0.000 description 1
- UMUPDNHBEPHDHD-UHFFFAOYSA-N C.C.C.CC(=O)C=O.CC1=CC=C(OC2=C(N)C=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C(O)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C=CN=C2)C=C1.CC1=CC=C(OC2=C([N+](=O)[O-])C=CN(O)=[C+]2)C=C1.CCN(CC)CC.Cl.ClC1=CC=CN=C1.O.O.O=S(=O)(O)O.O=[N+]([O-])C1=C(Cl)[C+]=N(O)C=C1.ON1=[C+]C(Cl)=CC=C1.ONOO.[HH].[NaH] Chemical compound C.C.C.CC(=O)C=O.CC1=CC=C(OC2=C(N)C=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C(O)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C=CN=C2)C=C1.CC1=CC=C(OC2=C([N+](=O)[O-])C=CN(O)=[C+]2)C=C1.CCN(CC)CC.Cl.ClC1=CC=CN=C1.O.O.O=S(=O)(O)O.O=[N+]([O-])C1=C(Cl)[C+]=N(O)C=C1.ON1=[C+]C(Cl)=CC=C1.ONOO.[HH].[NaH] UMUPDNHBEPHDHD-UHFFFAOYSA-N 0.000 description 1
- FCGARDFFGYELHK-UHFFFAOYSA-N C.C.C.CC(C)(C)O[K].CC1=NC=CC2=C1C=C(Br)S2.ClC1=NC=CC2=C1C=C(Br)S2.O=P(Cl)(Cl)Cl Chemical compound C.C.C.CC(C)(C)O[K].CC1=NC=CC2=C1C=C(Br)S2.ClC1=NC=CC2=C1C=C(Br)S2.O=P(Cl)(Cl)Cl FCGARDFFGYELHK-UHFFFAOYSA-N 0.000 description 1
- KCZANOYMDVULHU-UHFFFAOYSA-N C.C.C.CC1=C2C=C(C#N)SC2=CN=C1.CC1=C2C=C(C3=NN(C)NN3)SC2=CN=C1.CC1=C2C=C(C3=NN=NN3)SC2=CN=C1 Chemical compound C.C.C.CC1=C2C=C(C#N)SC2=CN=C1.CC1=C2C=C(C3=NN(C)NN3)SC2=CN=C1.CC1=C2C=C(C3=NN=NN3)SC2=CN=C1 KCZANOYMDVULHU-UHFFFAOYSA-N 0.000 description 1
- BADOVFAHPARXKM-ZBTMAAAFSA-M C.C.C.CC1=C2C=C(C(=O)NCCCl)SC2=CN=C1.CC1=C2C=C(C(=O)NCCN)SC2=CN=C1.CC1=C2C=C(C3=NC=CN3)SC2=CN=C1.CC1=C2C=C(C3=NC=CO3)SC2=CN=C1.CC1=C2C=C(C3=NCCN3)SC2=CN=C1.CC1=C2C=C(C3=NCCO3)SC2=CN=C1.COC(=O)C1=CC2=C(C)C=NC=C2S1.COC(=O)C1=CC2=C(C)C=NC=C2S1.ClCCl.ClCCl.O=[Ca].O=[Ni]=O.OOOO[Ba][Mn].[2H]B[U].[2H][2H] Chemical compound C.C.C.CC1=C2C=C(C(=O)NCCCl)SC2=CN=C1.CC1=C2C=C(C(=O)NCCN)SC2=CN=C1.CC1=C2C=C(C3=NC=CN3)SC2=CN=C1.CC1=C2C=C(C3=NC=CO3)SC2=CN=C1.CC1=C2C=C(C3=NCCN3)SC2=CN=C1.CC1=C2C=C(C3=NCCO3)SC2=CN=C1.COC(=O)C1=CC2=C(C)C=NC=C2S1.COC(=O)C1=CC2=C(C)C=NC=C2S1.ClCCl.ClCCl.O=[Ca].O=[Ni]=O.OOOO[Ba][Mn].[2H]B[U].[2H][2H] BADOVFAHPARXKM-ZBTMAAAFSA-M 0.000 description 1
- SSGFSNBLNINEHO-UHFFFAOYSA-M C.C.C.CCC1(C2=CC=C(O)C=C2)CC1.CCC1(C2=CC=C(OC3=CN=CC4=C3C=C(C(=O)OC)S4)C=C2)CC1.CCS[Na].CN.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3(CO)CC3)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3(CO)CC3)C=C2)S1.COC1=CC=C(C2(C(=O)O)CC2)C=C1.COC1=CC=C(C2(CO)CC2)C=C1.OCC1(C2=CC=C(O)C=C2)CC1.[Li]CI Chemical compound C.C.C.CCC1(C2=CC=C(O)C=C2)CC1.CCC1(C2=CC=C(OC3=CN=CC4=C3C=C(C(=O)OC)S4)C=C2)CC1.CCS[Na].CN.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3(CO)CC3)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3(CO)CC3)C=C2)S1.COC1=CC=C(C2(C(=O)O)CC2)C=C1.COC1=CC=C(C2(CO)CC2)C=C1.OCC1(C2=CC=C(O)C=C2)CC1.[Li]CI SSGFSNBLNINEHO-UHFFFAOYSA-M 0.000 description 1
- CRQSYGSXVIUFHZ-UHFFFAOYSA-N C.C.CC(=O)C1=CC2=C(C=NC=C2O)S1.COC(=O)C1=CC2=C(C=NC=C2O)S1.COC(=O)C1=CC2=C(C=NC=C2OC2CCCCO2)S1.Cl.ClC1=CC(OC2CCCCO2)=CN=C1.O=CC1=C(Cl)C=NC=C1OC1CCCCO1.OC1=CN=CC(Cl)=C1 Chemical compound C.C.CC(=O)C1=CC2=C(C=NC=C2O)S1.COC(=O)C1=CC2=C(C=NC=C2O)S1.COC(=O)C1=CC2=C(C=NC=C2OC2CCCCO2)S1.Cl.ClC1=CC(OC2CCCCO2)=CN=C1.O=CC1=C(Cl)C=NC=C1OC1CCCCO1.OC1=CN=CC(Cl)=C1 CRQSYGSXVIUFHZ-UHFFFAOYSA-N 0.000 description 1
- DMWMFCQVCNEVHV-UHFFFAOYSA-N C.C.CC1=C2C=C(C(=O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=C(C(=O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=C(C(O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=C(C(O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=C(C(O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=CSC2=CN=C1.CN.CN.CPC.C[N+](=O)[O-].C[N+](=O)[O-].C[N+](=O)[O-].C[N+](=O)[O-].[H]C(=O)C1=CC=CC=C1 Chemical compound C.C.CC1=C2C=C(C(=O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=C(C(=O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=C(C(O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=C(C(O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=C(C(O)C3=CC=CC=C3)SC2=CN=C1.CC1=C2C=CSC2=CN=C1.CN.CN.CPC.C[N+](=O)[O-].C[N+](=O)[O-].C[N+](=O)[O-].C[N+](=O)[O-].[H]C(=O)C1=CC=CC=C1 DMWMFCQVCNEVHV-UHFFFAOYSA-N 0.000 description 1
- JQXNHLQIQPQBQT-UHFFFAOYSA-N C.C.CC1=NC=CC2=C1C=C(C#N)S2.CC1=NC=CC2=C1C=C(C(N)=O)S2 Chemical compound C.C.CC1=NC=CC2=C1C=C(C#N)S2.CC1=NC=CC2=C1C=C(C(N)=O)S2 JQXNHLQIQPQBQT-UHFFFAOYSA-N 0.000 description 1
- WWEQGFQJIYUWCG-UHFFFAOYSA-M C.C.CCCOCCOCC.CCOCCOCCOCC1(C2=CC=C(O)C=C2)CC1.CCOCCOCCOCC1(C2=CC=C(OC)C=C2)CC1.CCOCCOCCOCC1(C2=CC=C(OC3=CN=CC4=C3C=C(C(=O)NC)S4)C=C2)CC1.CCOCCOCCOCC1(C2=CC=C(OC3=CN=CC4=C3C=C(C(=O)OC)S4)C=C2)CC1.COC1=CC=C(C2(CO)CC2)C=C1.CS[Na].[NaH] Chemical compound C.C.CCCOCCOCC.CCOCCOCCOCC1(C2=CC=C(O)C=C2)CC1.CCOCCOCCOCC1(C2=CC=C(OC)C=C2)CC1.CCOCCOCCOCC1(C2=CC=C(OC3=CN=CC4=C3C=C(C(=O)NC)S4)C=C2)CC1.CCOCCOCCOCC1(C2=CC=C(OC3=CN=CC4=C3C=C(C(=O)OC)S4)C=C2)CC1.COC1=CC=C(C2(CO)CC2)C=C1.CS[Na].[NaH] WWEQGFQJIYUWCG-UHFFFAOYSA-M 0.000 description 1
- PACBIXMGLBHAPR-LRMXAEHVSA-N C.CC(=O)C(=O)C1=C(Cl)C=NC=C1Cl.CC(=O)C(=O)C1=C(Cl)C=NC=C1OC1=CC=C(Cl)C=C1.CC(=O)C(=O)Cl.CC1=C(C(=O)O)C2=C(C=NC=C2O[Ar])S1.CC1=C(C)C2=C(C=NC=C2O[Ar])S1.CC1=C(C)C2=C(C=NC=C2O[Ar])S1.CO.COC(=O)C1=C(C(=O)O)C2=C(C=NC=C2O[Ar])S1.COC(=O)CS.ClC1=CN=CC(Cl)=C1.F.[3HH] Chemical compound C.CC(=O)C(=O)C1=C(Cl)C=NC=C1Cl.CC(=O)C(=O)C1=C(Cl)C=NC=C1OC1=CC=C(Cl)C=C1.CC(=O)C(=O)Cl.CC1=C(C(=O)O)C2=C(C=NC=C2O[Ar])S1.CC1=C(C)C2=C(C=NC=C2O[Ar])S1.CC1=C(C)C2=C(C=NC=C2O[Ar])S1.CO.COC(=O)C1=C(C(=O)O)C2=C(C=NC=C2O[Ar])S1.COC(=O)CS.ClC1=CN=CC(Cl)=C1.F.[3HH] PACBIXMGLBHAPR-LRMXAEHVSA-N 0.000 description 1
- APPLPZABIAOBPB-UHFFFAOYSA-M C.CC(=O)C1=CC2=C(C=NC=C2C)S1.CC1=CN=CC(Cl)=C1C=O.CC1=CN=CC2=C1C=C(C(=O)O)S2.CC1=CN=CC2=C1C=C(C(N)=O)S2.COC(=O)C1=CC2=C(C=NC=C2C)S1.COC(=O)CS.ClC1=CN=CC(Cl)=C1.O=CC1=C(Cl)C=NC=C1Cl.[Li]O Chemical compound C.CC(=O)C1=CC2=C(C=NC=C2C)S1.CC1=CN=CC(Cl)=C1C=O.CC1=CN=CC2=C1C=C(C(=O)O)S2.CC1=CN=CC2=C1C=C(C(N)=O)S2.COC(=O)C1=CC2=C(C=NC=C2C)S1.COC(=O)CS.ClC1=CN=CC(Cl)=C1.O=CC1=C(Cl)C=NC=C1Cl.[Li]O APPLPZABIAOBPB-UHFFFAOYSA-M 0.000 description 1
- CJBNKHDQYDFCCS-UHFFFAOYSA-N C.CC(=O)C1=NC2=C(OC3=CC=C(C)C=C3)C=NC=C2O1.CC1=CC=C(OC2=C(N)C(O)=CN=C2)C=C1.CC1=CC=C(OC2=C3N=C(C(N)=O)OC3=CN=C2)C=C1 Chemical compound C.CC(=O)C1=NC2=C(OC3=CC=C(C)C=C3)C=NC=C2O1.CC1=CC=C(OC2=C(N)C(O)=CN=C2)C=C1.CC1=CC=C(OC2=C3N=C(C(N)=O)OC3=CN=C2)C=C1 CJBNKHDQYDFCCS-UHFFFAOYSA-N 0.000 description 1
- NARVFJVLGDRTHB-UHFFFAOYSA-N C.CC(=O)O.CC(C)(C)OC(=O)C1=CC2=C(C(O)C3=CC=C(Cl)C=C3)C=NC=C2S1.CC(C)(C)OC(=O)C1=CC2=C(CC3=CC=C(Cl)C=C3)C=NC=C2S1.CO.COC(=O)C1=CC2=C(CC3=CC=C(Cl)C=C3)C=NC=C2S1.NC(=O)C1=CC2=C(CC3=CC=C(Cl)C=C3)C=NC=C2S1.O=S(=O)(O)O Chemical compound C.CC(=O)O.CC(C)(C)OC(=O)C1=CC2=C(C(O)C3=CC=C(Cl)C=C3)C=NC=C2S1.CC(C)(C)OC(=O)C1=CC2=C(CC3=CC=C(Cl)C=C3)C=NC=C2S1.CO.COC(=O)C1=CC2=C(CC3=CC=C(Cl)C=C3)C=NC=C2S1.NC(=O)C1=CC2=C(CC3=CC=C(Cl)C=C3)C=NC=C2S1.O=S(=O)(O)O NARVFJVLGDRTHB-UHFFFAOYSA-N 0.000 description 1
- HZAYNIGMZBZMOI-UHFFFAOYSA-M C.CC(C)(C)OC(=O)C1=CC2=C(C(O)C3=CC=C(Cl)C=C3)C=NC=C2S1.CC(C)(C)OC(=O)C1=CC2=C(C=O)C=NC=C2S1.CO.COC(=O)C1=CC2=C(C(=O)C3=CC=C(Cl)C=C3)C=NC=C2S1.COC(=O)C1=CC2=C(C(O)C3=CC=C(Cl)C=C3)C=NC=C2S1.ClC1=CC=C([Mg]Br)C=C1.NC(=O)C1=CC2=C(C(=O)C3=CC=C(Cl)C=C3)C=NC=C2S1.O=S(=O)(O)O Chemical compound C.CC(C)(C)OC(=O)C1=CC2=C(C(O)C3=CC=C(Cl)C=C3)C=NC=C2S1.CC(C)(C)OC(=O)C1=CC2=C(C=O)C=NC=C2S1.CO.COC(=O)C1=CC2=C(C(=O)C3=CC=C(Cl)C=C3)C=NC=C2S1.COC(=O)C1=CC2=C(C(O)C3=CC=C(Cl)C=C3)C=NC=C2S1.ClC1=CC=C([Mg]Br)C=C1.NC(=O)C1=CC2=C(C(=O)C3=CC=C(Cl)C=C3)C=NC=C2S1.O=S(=O)(O)O HZAYNIGMZBZMOI-UHFFFAOYSA-M 0.000 description 1
- TYDDUQREHOKQRI-YQGMIYHYSA-N C.COC(=O)/C=C/C1=CC2=C(OC3=CC=C(Br)C=C3)C=NC=C2S1.COC(=O)/C=P\P.Cl.N.NC(=O)/C=C/C1=CC2=C(OC3=CC=C(Br)C=C3)C=NC=C2S1.O=C(O)/C=C/C1=CC2=C(OC3=CC=C(Br)C=C3)C=NC=C2S1.[H]C(=O)C1=CC2=C(OC3=CC=C(Br)C=C3)C=NC=C2S1 Chemical compound C.COC(=O)/C=C/C1=CC2=C(OC3=CC=C(Br)C=C3)C=NC=C2S1.COC(=O)/C=P\P.Cl.N.NC(=O)/C=C/C1=CC2=C(OC3=CC=C(Br)C=C3)C=NC=C2S1.O=C(O)/C=C/C1=CC2=C(OC3=CC=C(Br)C=C3)C=NC=C2S1.[H]C(=O)C1=CC2=C(OC3=CC=C(Br)C=C3)C=NC=C2S1 TYDDUQREHOKQRI-YQGMIYHYSA-N 0.000 description 1
- YCTGWFIRXXYUCR-LRMXAEHVSA-L C.COC(=O)C1=CC2=C(Br)C=NC=C2S1.COC(=O)C1=CC2=C(C)C=NC=C2S1.COC(=O)C1=CC2=C([Cu](C#N)[Zn]Br)C=NC=C2S1.COC(=O)C1=CC2=C([Zn]Br)C=NC=C2S1.F.[3HH] Chemical compound C.COC(=O)C1=CC2=C(Br)C=NC=C2S1.COC(=O)C1=CC2=C(C)C=NC=C2S1.COC(=O)C1=CC2=C([Cu](C#N)[Zn]Br)C=NC=C2S1.COC(=O)C1=CC2=C([Zn]Br)C=NC=C2S1.F.[3HH] YCTGWFIRXXYUCR-LRMXAEHVSA-L 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N C1=CC=C2OCCC2=C1 Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- GKPRCYONVSCBPD-UHFFFAOYSA-N C1CC2CC1CN2.C1CC2CCC(C1)N2.C1CC2CCC1O2 Chemical compound C1CC2CC1CN2.C1CC2CCC(C1)N2.C1CC2CCC1O2 GKPRCYONVSCBPD-UHFFFAOYSA-N 0.000 description 1
- NKOHSZRAKODXFE-UHFFFAOYSA-N C=C(B(O)O)C1=CC=CC=C1.C=C(Br)C1=CC=CC=C1.C=C(C1=CC=CC=C1)C1=C2C=C(C(=O)OC)SC2=CN=C1.C=C(C1=CC=CC=C1)C1=C2C=C(C(N)=O)SC2=CN=C1.CC.CCC(O)(C1=CC=CC=C1)C1=C2C=C(C(N)=O)SC2=CN=C1.COC(=O)C1=CC2=C(Br)C=NC=C2S1.NC(=O)C1=CC2=C(C3(C4=CC=CC=C4)CO3)C=NC=C2S1 Chemical compound C=C(B(O)O)C1=CC=CC=C1.C=C(Br)C1=CC=CC=C1.C=C(C1=CC=CC=C1)C1=C2C=C(C(=O)OC)SC2=CN=C1.C=C(C1=CC=CC=C1)C1=C2C=C(C(N)=O)SC2=CN=C1.CC.CCC(O)(C1=CC=CC=C1)C1=C2C=C(C(N)=O)SC2=CN=C1.COC(=O)C1=CC2=C(Br)C=NC=C2S1.NC(=O)C1=CC2=C(C3(C4=CC=CC=C4)CO3)C=NC=C2S1 NKOHSZRAKODXFE-UHFFFAOYSA-N 0.000 description 1
- SWTBRBCDSAXOQE-UHFFFAOYSA-M C=C.CC(C)(C)OC(=O)C1=CC2=C(CO)C=NC=C2S1.CC(C)(C)OC(=O)C1=CC2=C(Cl)C=NC=C2S1.CCFB(F)F.CCO.CCOC(=O)C1=C2C=C(C(=O)OC(C)(C)C)SC2=CN=C1.COC(=O)C1=CC2=C(Cl)C=NC=C2S1.O=C(O)C1=CC2=C(Cl)C=NC=C2S1.[H]C(=O)C1=C(Cl)C=NC=C1Cl.[Li]O Chemical compound C=C.CC(C)(C)OC(=O)C1=CC2=C(CO)C=NC=C2S1.CC(C)(C)OC(=O)C1=CC2=C(Cl)C=NC=C2S1.CCFB(F)F.CCO.CCOC(=O)C1=C2C=C(C(=O)OC(C)(C)C)SC2=CN=C1.COC(=O)C1=CC2=C(Cl)C=NC=C2S1.O=C(O)C1=CC2=C(Cl)C=NC=C2S1.[H]C(=O)C1=C(Cl)C=NC=C1Cl.[Li]O SWTBRBCDSAXOQE-UHFFFAOYSA-M 0.000 description 1
- YPGADSJNQPIMOT-UHFFFAOYSA-N CC(=O)C1=C(C)C2=C(O)C=NC=C2S1.CC(=O)C1=C(Cl)C=NC=C1Cl.CC(=O)C1=C(O)C2=C(O)C=NC=C2S1.COC(=O)C1=C(C)C2=C(O)C=NC=C2S1.COC(=O)C1=C(O)C2=C(O)C=NC=C2S1.ClC1=CN=CC(Cl)=C1.[Ar].[Ar].[Ar].[Ar] Chemical compound CC(=O)C1=C(C)C2=C(O)C=NC=C2S1.CC(=O)C1=C(Cl)C=NC=C1Cl.CC(=O)C1=C(O)C2=C(O)C=NC=C2S1.COC(=O)C1=C(C)C2=C(O)C=NC=C2S1.COC(=O)C1=C(O)C2=C(O)C=NC=C2S1.ClC1=CN=CC(Cl)=C1.[Ar].[Ar].[Ar].[Ar] YPGADSJNQPIMOT-UHFFFAOYSA-N 0.000 description 1
- WWZCOISIKQDJLA-UHFFFAOYSA-N CC(=O)C1=C(C)C2=C(O)C=NC=C2S1.CC(=O)C1=C(Cl)C=NC=C1Cl.COC(=O)C1=C(C)C2=C(O)C=NC=C2S1.ClC1=CN=CC(Cl)=C1.[Ar].[Ar] Chemical compound CC(=O)C1=C(C)C2=C(O)C=NC=C2S1.CC(=O)C1=C(Cl)C=NC=C1Cl.COC(=O)C1=C(C)C2=C(O)C=NC=C2S1.ClC1=CN=CC(Cl)=C1.[Ar].[Ar] WWZCOISIKQDJLA-UHFFFAOYSA-N 0.000 description 1
- RJZOXTNWOIUTAM-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=NC(Cl)=C2OC2=CC=C(Br)C=C2)S1.CC(=O)C1=CC2=C(S1)C(Cl)=NC=C2OC1=CC=C(Br)C=C1.ClC1=CN=C(Cl)C(Cl)=C1.N.NC(=O)C1=CC2=C(C=NC(Cl)=C2OC2=CC=C(Br)C=C2)S1.[H]C(=O)C1=C(Cl)C(Cl)=NC=C1Cl Chemical compound CC(=O)C1=CC2=C(C=NC(Cl)=C2OC2=CC=C(Br)C=C2)S1.CC(=O)C1=CC2=C(S1)C(Cl)=NC=C2OC1=CC=C(Br)C=C1.ClC1=CN=C(Cl)C(Cl)=C1.N.NC(=O)C1=CC2=C(C=NC(Cl)=C2OC2=CC=C(Br)C=C2)S1.[H]C(=O)C1=C(Cl)C(Cl)=NC=C1Cl RJZOXTNWOIUTAM-UHFFFAOYSA-N 0.000 description 1
- PBFXHNZGAOYTTC-UHFFFAOYSA-N CC(C)(CO)NC(=O)C1=CC2=C(C=NC=C2O)S1.CC1(C)COC(C2=CC3=C(C=NC=C3O)S2)=N1.CC1=CN=CC2=C1C=C(C1=NC(C)(C)CO1)S2.O=S(Cl)Cl Chemical compound CC(C)(CO)NC(=O)C1=CC2=C(C=NC=C2O)S1.CC1(C)COC(C2=CC3=C(C=NC=C3O)S2)=N1.CC1=CN=CC2=C1C=C(C1=NC(C)(C)CO1)S2.O=S(Cl)Cl PBFXHNZGAOYTTC-UHFFFAOYSA-N 0.000 description 1
- XKLFAXCOHWKGKV-UHFFFAOYSA-N CC1=CC2=C(C=NC=C2C)S1.CC1=CN=CC2=C1C=C(C(=O)O)S2.CC1=CN=CC2=C1C=CS2 Chemical compound CC1=CC2=C(C=NC=C2C)S1.CC1=CN=CC2=C1C=C(C(=O)O)S2.CC1=CN=CC2=C1C=CS2 XKLFAXCOHWKGKV-UHFFFAOYSA-N 0.000 description 1
- JKBYDKHTFGNOPV-UHFFFAOYSA-N CC1=CC=C(OC2=C(N)C(N)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C(N)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C(O)=CN=C2)C=C1.CC1=CC=C(OC2=C3N=C(C(N)=O)NC3=CN=C2)C=C1.COC(=O)C1=NC2=C(OC3=CC=C(C)C=C3)C=NC=C2N1.Cl.N.O.O=S=O Chemical compound CC1=CC=C(OC2=C(N)C(N)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C(N)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C(O)=CN=C2)C=C1.CC1=CC=C(OC2=C3N=C(C(N)=O)NC3=CN=C2)C=C1.COC(=O)C1=NC2=C(OC3=CC=C(C)C=C3)C=NC=C2N1.Cl.N.O.O=S=O JKBYDKHTFGNOPV-UHFFFAOYSA-N 0.000 description 1
- VOKBJTFZCPGVJQ-UHFFFAOYSA-N CC1=CC=C(OC2=C(N)C(SC(=S)N(C)C)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C(SC(=S)N(C)C)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C=CN=C2)C=C1.CC1=CC=C(OC2=C3N=C(C(N)=O)SC3=CN=C2)C=C1.COC(=O)C(=O)NC1=C(OC2=CC=C(C)C=C2)C=NC=C1SC(=S)N(C)C.COC(=O)C1=NC2=C(OC3=CC=C(C)C=C3)C=NC=C2S1 Chemical compound CC1=CC=C(OC2=C(N)C(SC(=S)N(C)C)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C(SC(=S)N(C)C)=CN=C2)C=C1.CC1=CC=C(OC2=C(NC(=O)C(C)(C)C)C=CN=C2)C=C1.CC1=CC=C(OC2=C3N=C(C(N)=O)SC3=CN=C2)C=C1.COC(=O)C(=O)NC1=C(OC2=CC=C(C)C=C2)C=NC=C1SC(=S)N(C)C.COC(=O)C1=NC2=C(OC3=CC=C(C)C=C3)C=NC=C2S1 VOKBJTFZCPGVJQ-UHFFFAOYSA-N 0.000 description 1
- JFQAXQHKKHUTQA-UHFFFAOYSA-N CC1=CN=CC(Cl)=C1C=O.CC1=CN=CC2=C1C=C(C(N)=O)S2.CO.COC(=O)C1=CC2=C(C=NC=C2C)S1.COC(=O)CS.N Chemical compound CC1=CN=CC(Cl)=C1C=O.CC1=CN=CC2=C1C=C(C(N)=O)S2.CO.COC(=O)C1=CC2=C(C=NC=C2C)S1.COC(=O)CS.N JFQAXQHKKHUTQA-UHFFFAOYSA-N 0.000 description 1
- VEKHWPFYNZSOHK-OVMYSRIOSA-N CC1=CN=CC2=C1C=C(C(=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)S2.CC1=CN=CC2=C1C=C(C(=O)N[C@@H]1O[C@H](CO[Ac])[C@@H](O[Ac])[C@H](O[Ac])[C@H]1O[Ac])S2.CC1=CN=CC2=C1C=C(C(=O)O)S2.CN Chemical compound CC1=CN=CC2=C1C=C(C(=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)S2.CC1=CN=CC2=C1C=C(C(=O)N[C@@H]1O[C@H](CO[Ac])[C@@H](O[Ac])[C@H](O[Ac])[C@H]1O[Ac])S2.CC1=CN=CC2=C1C=C(C(=O)O)S2.CN VEKHWPFYNZSOHK-OVMYSRIOSA-N 0.000 description 1
- ACYOOGDSIUVFMS-UHFFFAOYSA-N CC1=CN=CC2=C1C=C(C(=O)O)S2 Chemical compound CC1=CN=CC2=C1C=C(C(=O)O)S2 ACYOOGDSIUVFMS-UHFFFAOYSA-N 0.000 description 1
- HOECBXQSFAMJOE-UHFFFAOYSA-N CCC1=CC=C(O)C=C1.CCC1=CC=C(OC2=CN=CC3=C2C=C(C(=O)OC)S3)C=C1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO)C=C2)S1.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO)C=C2)S1 Chemical compound CCC1=CC=C(O)C=C1.CCC1=CC=C(OC2=CN=CC3=C2C=C(C(=O)OC)S3)C=C1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO)C=C2)S1.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO)C=C2)S1 HOECBXQSFAMJOE-UHFFFAOYSA-N 0.000 description 1
- NQJFKNCACOOPLB-UHFFFAOYSA-N CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(/C(N)=N/O)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3=NCCN3)C=C2)S1.Cl.FCF.NO.[C-]#[N+]C1=CC=C(OC2=CN=CC3=C2C=C(C(=O)NC)S3)C=C1.[H]N(C)C(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3=NOC(F)=N3)C=C2)S1 Chemical compound CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(/C(N)=N/O)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3=NCCN3)C=C2)S1.Cl.FCF.NO.[C-]#[N+]C1=CC=C(OC2=CN=CC3=C2C=C(C(=O)NC)S3)C=C1.[H]N(C)C(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C3=NOC(F)=N3)C=C2)S1 NQJFKNCACOOPLB-UHFFFAOYSA-N 0.000 description 1
- GELTVXDGMPEISG-KBXBZICCSA-L CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(C)=O)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(Br)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(=O)N3CCOCC3)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(=O)O)C=C2)S1.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(=O)N3CCOCC3)C=C2)S1.[2H][Pd](Cl)(Cl)P(F)P.[H]N(C)C(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(=O)CC(C)(O)C3=CC=C(OC4=CN=CC5=C4C=C(C(=O)N([H])C)S5)C=C3)C=C2)S1 Chemical compound CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(C)=O)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(Br)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(=O)N3CCOCC3)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(=O)O)C=C2)S1.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(=O)N3CCOCC3)C=C2)S1.[2H][Pd](Cl)(Cl)P(F)P.[H]N(C)C(=O)C1=CC2=C(C=NC=C2OC2=CC=C(C(=O)CC(C)(O)C3=CC=C(OC4=CN=CC5=C4C=C(C(=O)N([H])C)S5)C=C3)C=C2)S1 GELTVXDGMPEISG-KBXBZICCSA-L 0.000 description 1
- FNKLXCSGRZPANB-QIXFAWKRSA-N CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO[C@H]3C[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO[C@H]3C[C@@H](O[Ac])[C@H](O[Ac])[C@@H](CO[Ac])O3)C=C2)S1 Chemical compound CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO[C@H]3C[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(CO[C@H]3C[C@@H](O[Ac])[C@H](O[Ac])[C@@H](CO[Ac])O3)C=C2)S1 FNKLXCSGRZPANB-QIXFAWKRSA-N 0.000 description 1
- HJODZXQTXJZXIV-UHFFFAOYSA-N CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(N3CCOCC3)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1 Chemical compound CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1.CNC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(N3CCOCC3)C=C2)S1.COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(I)C=C2)S1 HJODZXQTXJZXIV-UHFFFAOYSA-N 0.000 description 1
- KOCJLRYWCRTGSU-UHFFFAOYSA-N COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(COC3CCCCO3)C=C2)S1.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(COC3CCCCO3)C=C2)S1.OC1=CC=C(COC2CCCCO2)C=C1 Chemical compound COC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(COC3CCCCO3)C=C2)S1.NC(=O)C1=CC2=C(C=NC=C2OC2=CC=C(COC3CCCCO3)C=C2)S1.OC1=CC=C(COC2CCCCO2)C=C1 KOCJLRYWCRTGSU-UHFFFAOYSA-N 0.000 description 1
- PDCUGSSKBMUMQE-UHFFFAOYSA-N NC(=O)C1=CC2=C(C(O)(CO)C3=CC=CC=C3)C=NC=C2S1.O=[Os](=O)(=O)=O Chemical compound NC(=O)C1=CC2=C(C(O)(CO)C3=CC=CC=C3)C=NC=C2S1.O=[Os](=O)(=O)=O PDCUGSSKBMUMQE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/387,317 US20030220365A1 (en) | 1998-06-04 | 2003-03-12 | Cell adhesion-inhibiting antiinflammatory compounds |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8790798P | 1998-06-04 | 1998-06-04 | |
| US09/325,336 US6232320B1 (en) | 1998-06-04 | 1999-06-03 | Cell adhesion-inhibiting antiinflammatory compounds |
| US09/799,729 US6579882B2 (en) | 1998-06-04 | 2001-03-06 | Cell adhesion-inhibiting antiinflammatory compounds |
| US10/387,317 US20030220365A1 (en) | 1998-06-04 | 2003-03-12 | Cell adhesion-inhibiting antiinflammatory compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/799,729 Division US6579882B2 (en) | 1998-06-04 | 2001-03-06 | Cell adhesion-inhibiting antiinflammatory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030220365A1 true US20030220365A1 (en) | 2003-11-27 |
Family
ID=26777511
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/325,336 Expired - Lifetime US6232320B1 (en) | 1998-06-04 | 1999-06-03 | Cell adhesion-inhibiting antiinflammatory compounds |
| US09/799,729 Expired - Fee Related US6579882B2 (en) | 1998-06-04 | 2001-03-06 | Cell adhesion-inhibiting antiinflammatory compounds |
| US10/387,317 Abandoned US20030220365A1 (en) | 1998-06-04 | 2003-03-12 | Cell adhesion-inhibiting antiinflammatory compounds |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/325,336 Expired - Lifetime US6232320B1 (en) | 1998-06-04 | 1999-06-03 | Cell adhesion-inhibiting antiinflammatory compounds |
| US09/799,729 Expired - Fee Related US6579882B2 (en) | 1998-06-04 | 2001-03-06 | Cell adhesion-inhibiting antiinflammatory compounds |
Country Status (1)
| Country | Link |
|---|---|
| US (3) | US6232320B1 (US20030220365A1-20031127-C00011.png) |
Cited By (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050282820A1 (en) * | 2004-06-17 | 2005-12-22 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| US20060058341A1 (en) * | 2004-09-15 | 2006-03-16 | Connolly Peter J | Thiazolopyridine kinase inhibitors |
| WO2006046035A1 (en) * | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds |
| US20060111355A1 (en) * | 2004-11-23 | 2006-05-25 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US20060189617A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189618A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189616A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | 7-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US20060264631A1 (en) * | 2005-05-18 | 2006-11-23 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US20060270848A1 (en) * | 2005-05-26 | 2006-11-30 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor |
| WO2007088345A1 (en) | 2006-01-31 | 2007-08-09 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| WO2007122410A1 (en) | 2006-04-26 | 2007-11-01 | F.Hoffmann-La Roche Ag | Pyrimidine derivatives as pi3k inhibitors |
| WO2007127175A3 (en) * | 2006-04-26 | 2007-12-27 | Piramed Ltd | Pharmaceutical compounds |
| US20080221097A1 (en) * | 2005-08-09 | 2008-09-11 | Glaxo Group Limited | Imidazopyridine Derivatives as Cannabinoid Receptor Ligands |
| US20080242695A1 (en) * | 2007-03-30 | 2008-10-02 | Morgan Bradley P | Certain Chemical Entities, Compositions, and Methods |
| US20080255143A1 (en) * | 2003-07-29 | 2008-10-16 | Smithkline Beecham Corporation | Inhibitors of Akt Activity |
| US20090029345A1 (en) * | 2006-08-01 | 2009-01-29 | Alan Russell | Modulating skeletal muscle |
| WO2009013462A1 (en) * | 2007-07-23 | 2009-01-29 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| WO2009042607A1 (en) | 2007-09-24 | 2009-04-02 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| US20090209607A1 (en) * | 2007-02-07 | 2009-08-20 | Seefeld Mark A | Inhibitors of akt activity |
| US7589206B2 (en) | 2004-06-09 | 2009-09-15 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| US7696210B2 (en) | 2004-06-17 | 2010-04-13 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US20100093741A1 (en) * | 2006-08-02 | 2010-04-15 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| US20100197754A1 (en) * | 2009-01-30 | 2010-08-05 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| US7795245B2 (en) | 2005-05-20 | 2010-09-14 | Atlantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2010105008A2 (en) | 2009-03-12 | 2010-09-16 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| WO2010138589A1 (en) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| US20110014212A1 (en) * | 2006-08-02 | 2011-01-20 | Aaron Hinken | Certain Chemical Entities, Compositions and Methods |
| US20110021496A1 (en) * | 2007-10-26 | 2011-01-27 | F. Hoffmann-La Roche Ag | Thienopyrimidine derivatives as p13k inhibitors |
| US20110021558A1 (en) * | 2008-01-21 | 2011-01-27 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| US20110172191A1 (en) * | 2008-06-19 | 2011-07-14 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| WO2011130654A1 (en) | 2010-04-16 | 2011-10-20 | Genentech, Inc. | Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy |
| WO2012088254A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
| EP2518074A1 (en) | 2006-12-07 | 2012-10-31 | F. Hoffmann-La Roche AG | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
| WO2014130923A2 (en) | 2013-02-25 | 2014-08-28 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
| US9290496B2 (en) | 2013-11-21 | 2016-03-22 | Pfizer Inc. | Purine derivatives |
| US9428512B2 (en) | 2012-11-20 | 2016-08-30 | Glaxosmithkline Llc | Compounds |
| US9540383B2 (en) | 2012-11-20 | 2017-01-10 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| US9555036B2 (en) | 2012-08-24 | 2017-01-31 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
| US9877968B2 (en) | 2008-08-11 | 2018-01-30 | Glaxosmithkline Llc | 6-amino-purin-8-one compounds |
| US10112946B2 (en) | 2011-07-22 | 2018-10-30 | Glaxosmithkline Llc | Composition |
| US10272082B2 (en) | 2011-07-13 | 2019-04-30 | Cytokinetics, Inc. | Combination ALS therapy |
| US10709714B2 (en) | 2013-11-22 | 2020-07-14 | Clifton Life Sciences LLC | Gastrin antagonists for treatment and prevention of osteoporosis |
Families Citing this family (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162795A1 (en) * | 1998-10-22 | 2003-08-28 | Pfizer Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| CN1615873A (zh) | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
| EP1343502A2 (en) * | 2000-11-17 | 2003-09-17 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0117583D0 (en) * | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| WO2003059874A2 (en) | 2001-12-21 | 2003-07-24 | Pharmacia Corporation | Aromatic thioether liver x-receptor modulators |
| CA2477721A1 (en) * | 2002-03-07 | 2003-09-12 | F. Hoffmann-La Roche Ag | Bicyclic pyridine and pyrimidine p38 kinase inhibitors |
| DE60335099D1 (de) * | 2002-05-06 | 2011-01-05 | Vertex Pharma | Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren |
| MXPA04011690A (es) * | 2002-05-24 | 2005-03-31 | Pharmacia Corp | Moduladores de receptor x de higado de sulfona. |
| MXPA04011691A (es) * | 2002-05-24 | 2005-09-12 | Pharmacia Corp | Moduladores del receptor x anilino hepaticos. |
| PL373424A1 (en) * | 2002-06-06 | 2005-08-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| US6974870B2 (en) * | 2002-06-06 | 2005-12-13 | Boehringer Ingelheim Phamaceuticals, Inc. | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| CA2499213A1 (en) * | 2002-09-17 | 2004-04-01 | Pharmacia Corporation | Aromatic liver x-receptor modulators |
| SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| NZ541218A (en) * | 2003-01-17 | 2008-05-30 | Astrazeneca Ab | Thienopyrimidinediones and their use in modulation of autoimmune disease |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) * | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| IL154306A0 (en) * | 2003-02-05 | 2003-09-17 | Rimonyx Pharmaceuticals Ltd | Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| GB0315950D0 (en) * | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
| JP5189765B2 (ja) * | 2003-08-01 | 2013-04-24 | バイオコン・リミテッド | 加水分解可能なプロドラッグのためのアリールカルバメートオリゴマーおよびこれを含むプロドラッグ |
| EP1682510A2 (en) * | 2003-11-10 | 2006-07-26 | Wyeth | Methods and compositions for selectin inhibition |
| KR20060108666A (ko) * | 2003-11-10 | 2006-10-18 | 와이어쓰 | 셀렉틴 억제방법 및 이를 위한 조성물 |
| AU2004297250A1 (en) * | 2003-12-05 | 2005-06-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds as IKK inhibitors |
| DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
| EP1718608B1 (en) * | 2004-02-20 | 2013-07-17 | Boehringer Ingelheim International GmbH | Viral polymerase inhibitors |
| DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| KR100822681B1 (ko) * | 2004-05-04 | 2008-04-17 | 에프. 호프만-라 로슈 아게 | Ｉｋｋ 억제제로서의 티에노피리다진 |
| RU2006142741A (ru) * | 2004-05-04 | 2008-06-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Тиенопиридины как ингибиторы ikk |
| US20050256154A1 (en) * | 2004-05-04 | 2005-11-17 | Kin-Chun Luk | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
| WO2005110410A2 (en) * | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| US7488736B2 (en) * | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| GB0412467D0 (en) * | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| AR049300A1 (es) * | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| WO2006004903A2 (en) * | 2004-06-28 | 2006-01-12 | Atherogenics, Inc. | 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| JP5096142B2 (ja) * | 2004-07-30 | 2012-12-12 | メチルジーン インコーポレイテッド | Ｖｅｇｆレセプターおよびｈｇｆレセプターシグナル伝達の阻害剤 |
| US7465726B2 (en) * | 2004-08-02 | 2008-12-16 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2.3-B]pyridines |
| US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| BRPI0516242B1 (pt) * | 2004-10-21 | 2014-10-07 | Dow Agrosciences Llc | Compostos tieno-pirimidina com atividade fungicida, bem como composição fungicida e método para o controle ou prevenção de ataque fúngico |
| US7674822B2 (en) * | 2004-11-24 | 2010-03-09 | Wyeth | PTP1b inhibitors |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| ES2623221T3 (es) * | 2005-05-20 | 2017-07-10 | Methylgene Inc | Inhibidores de la señalización del receptor de VEGF y del receptor de HGF |
| ES2473341T3 (es) * | 2005-05-20 | 2014-07-04 | Methylgene Inc | Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF |
| BRPI0609802A2 (pt) * | 2005-05-20 | 2017-05-02 | Alantos Pharmaceuticals Holding Inc | composto, composição farmacêutica e uso de um composto |
| KR20080026654A (ko) * | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
| CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| JP5015154B2 (ja) * | 2005-08-12 | 2012-08-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
| KR100995790B1 (ko) * | 2005-08-16 | 2010-11-22 | 에프. 호프만-라 로슈 아게 | 신규한 4-아미노-티에노[3,2-ｃ]피리딘-7-카르복실산아미드 |
| EP1934228A2 (en) * | 2005-09-01 | 2008-06-25 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
| EP1926735A1 (en) | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| EP1963320A1 (en) * | 2005-12-07 | 2008-09-03 | OSI Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
| MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
| US20080108611A1 (en) * | 2006-01-19 | 2008-05-08 | Battista Kathleen A | Substituted thienopyrimidine kinase inhibitors |
| KR100846988B1 (ko) * | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
| AU2007224020A1 (en) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| PE20080145A1 (es) * | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| AR060061A1 (es) * | 2006-03-22 | 2008-05-21 | Methylgene Inc | Inhibidores de la actividad de la proteina tirosina quinasa |
| UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| EP2029608A1 (en) * | 2006-06-06 | 2009-03-04 | Boehringer Ingelheim International GmbH | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use |
| US7932390B2 (en) * | 2006-06-29 | 2011-04-26 | Hoffman-La Roche Inc. | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives |
| EP2044086A2 (en) * | 2006-06-30 | 2009-04-08 | Janssen Pharmaceutica N.V. | Thiazolopyrimidine modulators of trpv1 |
| US20080125454A1 (en) * | 2006-10-05 | 2008-05-29 | Wyeth | Methods and Compositions for Treatment of Scleritis and Related Disorders |
| US8513270B2 (en) * | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
| WO2008086053A1 (en) * | 2007-01-03 | 2008-07-17 | Virobay, Inc. | Hcv inhibitors |
| SI2125792T1 (sl) * | 2007-02-19 | 2011-03-31 | Glaxosmithkline Llc | Purinski derivati kot imunomodulatorji |
| EP3495369B1 (en) * | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| DE102007027800A1 (de) * | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
| DE102007027799A1 (de) * | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
| MX2010001636A (es) * | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos. |
| EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| EP2332536A1 (en) * | 2008-03-05 | 2011-06-15 | MethylGene Inc. | Inhibitors of protein tyrosine kinase activity |
| SI2288610T1 (sl) | 2008-03-11 | 2016-11-30 | Incyte Holdings Corporation | Derivati azetidina in ciklobutana kot inhibitorji jak |
| SG193149A1 (en) * | 2008-08-11 | 2013-09-30 | Glaxosmithkline Llc | Novel adenine derivatives |
| US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
| CN102203095A (zh) * | 2008-08-11 | 2011-09-28 | 葛兰素史密丝克莱恩有限责任公司 | 用于治疗变应性疾病、炎性疾病和感染性疾病的嘌呤衍生物 |
| EP2326646B1 (en) * | 2008-08-11 | 2013-07-31 | GlaxoSmithKline LLC | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2010065743A2 (en) * | 2008-12-03 | 2010-06-10 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
| EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
| MX2011012262A (es) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak). |
| WO2010151317A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2010151318A1 (en) * | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2011005660A1 (en) | 2009-07-08 | 2011-01-13 | Valocor Therapeutics, Inc. | Tofa analogs useful in treating dermatological disorders or conditions |
| TW201113285A (en) * | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| PT2486041E (pt) | 2009-10-09 | 2013-11-14 | Incyte Corp | Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo |
| WO2011098451A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| EA023444B1 (ru) * | 2010-02-18 | 2016-06-30 | Инсайт Холдингс Корпорейшн | Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения |
| SI3354652T1 (sl) * | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
| SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
| TW201219401A (en) | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
| BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| US8778931B2 (en) | 2010-12-22 | 2014-07-15 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| PT3738434T (pt) | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| CN102702223A (zh) * | 2012-05-28 | 2012-10-03 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-溴-4-氯噻吩并[3,2-c]吡啶的制备方法 |
| CN104837839A (zh) | 2012-11-08 | 2015-08-12 | 辉瑞公司 | 作为多巴胺d1配体的杂芳族化合物 |
| US20150291625A1 (en) | 2012-11-08 | 2015-10-15 | Pfizer Inc. | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands |
| SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
| EP2958921B1 (en) | 2013-02-22 | 2017-09-20 | Pfizer Inc | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus kinases (jak) |
| EA030705B1 (ru) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Способы и промежуточные соединения при получении ингибитора jak |
| JP6320506B2 (ja) | 2013-03-12 | 2018-05-09 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20160078A1 (es) | 2013-03-15 | 2016-03-02 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA033555B1 (ru) | 2013-03-15 | 2019-10-31 | Global Blood Therapeutics Inc | Фармацевтические композиции для лечения серповидно-клеточного нарушения |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| ES2792549T3 (es) | 2013-08-07 | 2020-11-11 | Incyte Corp | Formas de dosificación de liberación sostenida para un inhibidor de JAK1 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| MY189995A (en) | 2014-02-07 | 2022-03-22 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| KR20160142401A (ko) | 2014-04-25 | 2016-12-12 | 화이자 인코포레이티드 | 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| CN106795165B (zh) | 2014-08-06 | 2019-09-10 | 辉瑞公司 | 咪唑并哒嗪化合物 |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| CN107001330A (zh) | 2014-09-17 | 2017-08-01 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| AP2017009749A0 (en) | 2014-12-11 | 2017-02-28 | Natco Pharma Ltd | 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| GB2575196B (en) * | 2015-08-17 | 2020-06-03 | Univ Holy Ghost Duquesne | Thieno pyridimine compounds and manufacture of the same |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| US10154992B2 (en) * | 2016-07-12 | 2018-12-18 | The Regents Of The University Of California | Compounds and methods for treating HIV infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| PL3746429T3 (pl) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu) |
| EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
| ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Citations (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318883A (en) * | 1962-07-04 | 1967-05-09 | Boehringer Sohn Ingelheim | Novel dihydrothieno[3, 2-d]pyrimidines |
| US3401030A (en) * | 1964-09-09 | 1968-09-10 | Union Carbide Corp | Method of defoliating cotton plants |
| US3459759A (en) * | 1965-11-24 | 1969-08-05 | Shell Oil Co | Certain substituted imidazo-(4,5-b or c)pyridines |
| US3470183A (en) * | 1966-06-09 | 1969-09-30 | Burroughs Wellcome Co | Thienopyrimidines |
| US3845065A (en) * | 1972-02-18 | 1974-10-29 | Merck & Co Inc | 4-oxo-4,5-dihydrothieno(3,2-c)pyridines |
| US3891660A (en) * | 1974-02-07 | 1975-06-24 | Squibb & Sons Inc | Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters |
| US3903095A (en) * | 1972-02-18 | 1975-09-02 | Merck & Co Inc | Certain substituted-thieno{8 3,2-c{9 -pyridines |
| US3998835A (en) * | 1975-04-08 | 1976-12-21 | Sandoz Ltd. | 1-Substituted amino-3-thieno-[3,2-c]pyridinyloxy-2-propanols |
| US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| US4375544A (en) * | 1978-01-28 | 1983-03-01 | Croda Synthetic Chemicals Limited | Fused pyridines |
| US4496568A (en) * | 1977-12-19 | 1985-01-29 | Pacor | Antiinflammatory thieno [2,3-c]pyridine derivatives |
| US4808595A (en) * | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
| US4876067A (en) * | 1986-09-12 | 1989-10-24 | Boehringer Mannheim Gmbh | Multilayer test strip device with a dissolvable reagent layer |
| US4935431A (en) * | 1988-02-25 | 1990-06-19 | Smithkline Beckman Intercredit B.V. | Substituted 7-amino-thienopyridine derivatives as gastric acid secretion inhibitors |
| US4988707A (en) * | 1989-09-13 | 1991-01-29 | G. D. Searle & Co. | Pharmacologically active phenylalkanoyl substituted imidazo (4,5-C) pyridines |
| US5006532A (en) * | 1987-01-30 | 1991-04-09 | Merck & Co. Inc., Inc. | Derivatives of 3-hydroxyazabenzo(beta)thiophene useful as 5-lipoxygenase inhibitors |
| US5026698A (en) * | 1988-11-02 | 1991-06-25 | Nissan Chemical Industries, Ltd. | Thienopyridine type mevalonolactones |
| US5079255A (en) * | 1989-06-29 | 1992-01-07 | Meiji Seika Kabushiki Kaisha | Thiazolo [4,5-6] pyridine derivatives and anti-ulcerative composition containing same |
| US5227384A (en) * | 1988-03-14 | 1993-07-13 | G. D. Searle & Co. | 5-substituted [4,5-c] imidazopyridines and pharmaceutical use thereof |
| US5280026A (en) * | 1989-05-30 | 1994-01-18 | Smithkline Beecham Intercredit B.V. | Thienopyrimidines |
| US5324727A (en) * | 1991-09-26 | 1994-06-28 | Mitsubishi Chem Ind | 3,6-disubstituted pyridazine derivatives |
| US5506238A (en) * | 1989-09-29 | 1996-04-09 | Eisai Co., Ltd. | Biphenylmethane derivative and pharmacological use |
| US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| US5714495A (en) * | 1995-04-14 | 1998-02-03 | Adir Et Compagnie | Pyridine compounds as melatonergic agents |
| US5747486A (en) * | 1994-11-08 | 1998-05-05 | Takeda Chemical Industries | Thienopyridine or thienopyrimidine derivatives and their use |
| US5801057A (en) * | 1996-03-22 | 1998-09-01 | Smart; Wilson H. | Microsampling device and method of construction |
| US5869486A (en) * | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE257830C (US20030220365A1-20031127-C00011.png) | ||||
| FR1453897A (fr) | 1965-06-16 | 1966-07-22 | Dérivés du thiophène et de thiéno pyridazines | |
| AR208500A1 (es) | 1972-06-14 | 1977-02-15 | Merck & Co Inc | Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas |
| FR2334356A1 (fr) | 1975-12-10 | 1977-07-08 | Parcor | Medicament a base de thieno-pyridine |
| FR2336132A1 (fr) | 1975-12-23 | 1977-07-22 | Parcor | Thieno (2,3-g) et (3,2-g) indolizines, leur procede de preparation et leurs applications |
| FR2452490A1 (fr) | 1979-03-30 | 1980-10-24 | Sanofi Sa | Nouveaux derives des thieno(2,3-c) et 3,2-c) pyridines, leur procede de preparation et leur application therapeutique |
| ATE143289T1 (de) | 1984-06-13 | 1996-10-15 | Applied Research Systems | Vorrichtung, mit verwendung in chemischen prüfverfahren |
| DE3533331A1 (de) | 1985-09-18 | 1987-03-26 | Heumann Ludwig & Co Gmbh | Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US4804658A (en) | 1986-09-15 | 1989-02-14 | G. D. Searle & Co. | Imidazopyridine derivatives and pharmaceutical compositions |
| DD257830A1 (de) | 1987-03-02 | 1988-06-29 | Univ Leipzig | Verfahren zur herstellung von 3-(funktionalisiert)alkyl-pyrido-/3',2':4,5/thieno/3,2-d/pyrimidin-4(3h)-onen |
| GB8712747D0 (en) | 1987-05-30 | 1987-07-01 | Pfizer Ltd | Therapeutic agents |
| MY104933A (en) | 1987-09-30 | 1994-07-30 | Pfizer Ltd | Platelet activating factor antagonists |
| ATE118006T1 (de) | 1988-03-15 | 1995-02-15 | Searle & Co | 1h/3h-(4-(n,n-cycloalkyl und/oder verzweigtes alkylcarboxamido)-benzyl>imdazo(4,5-c>pyridine als paf-antagonisten. |
| EP0388909A3 (en) | 1989-03-22 | 1991-05-08 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |
| DE4008726A1 (de) * | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
| US5585492A (en) | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
| DE19629657A1 (de) | 1996-07-23 | 1998-01-29 | Boehringer Mannheim Gmbh | Volumenunabhängiger diagnostischer Testträger und Verfahren zur Bestimmung von Analyt mit dessen Hilfe |
| DE69723863T2 (de) | 1996-11-06 | 2004-04-15 | Darwin Discovery Ltd., Slough | Chinoline und deren therapeutische verwendung |
| ATE227844T1 (de) | 1997-02-06 | 2002-11-15 | Therasense Inc | Kleinvolumiger sensor zur in-vitro bestimmung |
| SK18542000A3 (sk) | 1998-06-04 | 2001-12-03 | Abbott Laboratories | Protizápalové zlúčeniny inhibujúce bunkovú adhéziu |
-
1999
- 1999-06-03 US US09/325,336 patent/US6232320B1/en not_active Expired - Lifetime
-
2001
- 2001-03-06 US US09/799,729 patent/US6579882B2/en not_active Expired - Fee Related
-
2003
- 2003-03-12 US US10/387,317 patent/US20030220365A1/en not_active Abandoned
Patent Citations (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318883A (en) * | 1962-07-04 | 1967-05-09 | Boehringer Sohn Ingelheim | Novel dihydrothieno[3, 2-d]pyrimidines |
| US3401030A (en) * | 1964-09-09 | 1968-09-10 | Union Carbide Corp | Method of defoliating cotton plants |
| US3459759A (en) * | 1965-11-24 | 1969-08-05 | Shell Oil Co | Certain substituted imidazo-(4,5-b or c)pyridines |
| US3470183A (en) * | 1966-06-09 | 1969-09-30 | Burroughs Wellcome Co | Thienopyrimidines |
| US3845065A (en) * | 1972-02-18 | 1974-10-29 | Merck & Co Inc | 4-oxo-4,5-dihydrothieno(3,2-c)pyridines |
| US3903095A (en) * | 1972-02-18 | 1975-09-02 | Merck & Co Inc | Certain substituted-thieno{8 3,2-c{9 -pyridines |
| US3891660A (en) * | 1974-02-07 | 1975-06-24 | Squibb & Sons Inc | Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters |
| US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| US3998835A (en) * | 1975-04-08 | 1976-12-21 | Sandoz Ltd. | 1-Substituted amino-3-thieno-[3,2-c]pyridinyloxy-2-propanols |
| US4496568A (en) * | 1977-12-19 | 1985-01-29 | Pacor | Antiinflammatory thieno [2,3-c]pyridine derivatives |
| US4375544A (en) * | 1978-01-28 | 1983-03-01 | Croda Synthetic Chemicals Limited | Fused pyridines |
| US4876067A (en) * | 1986-09-12 | 1989-10-24 | Boehringer Mannheim Gmbh | Multilayer test strip device with a dissolvable reagent layer |
| US4808595A (en) * | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
| US5006532A (en) * | 1987-01-30 | 1991-04-09 | Merck & Co. Inc., Inc. | Derivatives of 3-hydroxyazabenzo(beta)thiophene useful as 5-lipoxygenase inhibitors |
| US4935431A (en) * | 1988-02-25 | 1990-06-19 | Smithkline Beckman Intercredit B.V. | Substituted 7-amino-thienopyridine derivatives as gastric acid secretion inhibitors |
| US5227384A (en) * | 1988-03-14 | 1993-07-13 | G. D. Searle & Co. | 5-substituted [4,5-c] imidazopyridines and pharmaceutical use thereof |
| US5026698A (en) * | 1988-11-02 | 1991-06-25 | Nissan Chemical Industries, Ltd. | Thienopyridine type mevalonolactones |
| US5280026A (en) * | 1989-05-30 | 1994-01-18 | Smithkline Beecham Intercredit B.V. | Thienopyrimidines |
| US5079255A (en) * | 1989-06-29 | 1992-01-07 | Meiji Seika Kabushiki Kaisha | Thiazolo [4,5-6] pyridine derivatives and anti-ulcerative composition containing same |
| US4988707A (en) * | 1989-09-13 | 1991-01-29 | G. D. Searle & Co. | Pharmacologically active phenylalkanoyl substituted imidazo (4,5-C) pyridines |
| US5506238A (en) * | 1989-09-29 | 1996-04-09 | Eisai Co., Ltd. | Biphenylmethane derivative and pharmacological use |
| US5324727A (en) * | 1991-09-26 | 1994-06-28 | Mitsubishi Chem Ind | 3,6-disubstituted pyridazine derivatives |
| US5747486A (en) * | 1994-11-08 | 1998-05-05 | Takeda Chemical Industries | Thienopyridine or thienopyrimidine derivatives and their use |
| US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| US5869486A (en) * | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
| US5714495A (en) * | 1995-04-14 | 1998-02-03 | Adir Et Compagnie | Pyridine compounds as melatonergic agents |
| US5801057A (en) * | 1996-03-22 | 1998-09-01 | Smart; Wilson H. | Microsampling device and method of construction |
Cited By (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255143A1 (en) * | 2003-07-29 | 2008-10-16 | Smithkline Beecham Corporation | Inhibitors of Akt Activity |
| US7589206B2 (en) | 2004-06-09 | 2009-09-15 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| US7696210B2 (en) | 2004-06-17 | 2010-04-13 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US20050282820A1 (en) * | 2004-06-17 | 2005-12-22 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| US7714130B2 (en) | 2004-06-17 | 2010-05-11 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| US20060058341A1 (en) * | 2004-09-15 | 2006-03-16 | Connolly Peter J | Thiazolopyridine kinase inhibitors |
| US7659284B2 (en) | 2004-09-15 | 2010-02-09 | Janssen Pharmaceutica Nv | Thiazolopyridine kinase inhibitors |
| US8153629B2 (en) | 2004-10-25 | 2012-04-10 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| JP2008517894A (ja) * | 2004-10-25 | 2008-05-29 | パイレームド リミテッド | 医薬化合物 |
| US7750002B2 (en) | 2004-10-25 | 2010-07-06 | Piramed Limited | Pharmaceutical compounds |
| US20100280027A1 (en) * | 2004-10-25 | 2010-11-04 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| WO2006046040A1 (en) * | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds |
| US8101607B2 (en) | 2004-10-25 | 2012-01-24 | F. Hoffman-La Roche Ag | Pharmaceutical compounds |
| CN101087794B (zh) * | 2004-10-25 | 2011-05-18 | 霍夫曼-拉罗奇有限公司 | 药用化合物 |
| US20090131429A1 (en) * | 2004-10-25 | 2009-05-21 | Stephen Shutteleworth | Pharmaceutical compounds |
| WO2006046031A1 (en) * | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds |
| JP2008517893A (ja) * | 2004-10-25 | 2008-05-29 | パイレームド リミテッド | 医薬化合物 |
| JP2008517892A (ja) * | 2004-10-25 | 2008-05-29 | パイレームド リミテッド | 医薬化合物 |
| US7776856B2 (en) | 2004-10-25 | 2010-08-17 | F. Hoffman-La Roche Ag | Pharmaceutical compounds |
| US20080207611A1 (en) * | 2004-10-25 | 2008-08-28 | Plramed Limited | Pharmaceutical compounds |
| US20080207609A1 (en) * | 2004-10-25 | 2008-08-28 | Plramed Limited | Pharmaceutical compounds |
| AU2005298408B2 (en) * | 2004-10-25 | 2012-08-23 | F. Hoffman-La Roche Ag | Pharmaceutical compounds |
| US7872003B2 (en) | 2004-10-25 | 2011-01-18 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| WO2006046035A1 (en) * | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds |
| AU2005298404B2 (en) * | 2004-10-25 | 2012-08-23 | F. Hoffman-La Roche Ag | Pharmaceutical compounds |
| US8946217B2 (en) | 2004-10-25 | 2015-02-03 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| KR101466529B1 (ko) | 2004-10-25 | 2014-11-27 | 에프. 호프만-라 로슈 아게 | 약학적 화합물 |
| US20060111355A1 (en) * | 2004-11-23 | 2006-05-25 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189617A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189618A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189616A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | 7-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US20060264631A1 (en) * | 2005-05-18 | 2006-11-23 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US8835441B2 (en) | 2005-05-20 | 2014-09-16 | Amgen Inc. | Heterobicyclic metalloprotease inhibitors |
| US7795245B2 (en) | 2005-05-20 | 2010-09-14 | Atlantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
| US20060270848A1 (en) * | 2005-05-26 | 2006-11-30 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| US20080221097A1 (en) * | 2005-08-09 | 2008-09-11 | Glaxo Group Limited | Imidazopyridine Derivatives as Cannabinoid Receptor Ligands |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| US8604051B2 (en) | 2006-01-31 | 2013-12-10 | Ucb Pharma S.A. | Thieno-pyridine derivatives as MEK inhibitors |
| US20090149437A1 (en) * | 2006-01-31 | 2009-06-11 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| US8394822B2 (en) | 2006-01-31 | 2013-03-12 | Ucb Pharma, S.A. | Thieno-pyridine derivatives as MEK inhibitors |
| WO2007088345A1 (en) | 2006-01-31 | 2007-08-09 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| US8283359B2 (en) | 2006-01-31 | 2012-10-09 | Ucb Pharma S.A. | Thieno-pyridine derivatives as MEK inhibitors |
| WO2007127175A3 (en) * | 2006-04-26 | 2007-12-27 | Piramed Ltd | Pharmaceutical compounds |
| US8252792B2 (en) | 2006-04-26 | 2012-08-28 | F. Hoffman-La Roche Ag | Pyrimidine derivatives as PI3K inhibitors |
| US20100016306A1 (en) * | 2006-04-26 | 2010-01-21 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as pi3k inhibitors |
| US8802670B2 (en) | 2006-04-26 | 2014-08-12 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| US9943519B2 (en) | 2006-04-26 | 2018-04-17 | Genentech, Inc. | Pharmaceutical compounds |
| US20080076758A1 (en) * | 2006-04-26 | 2008-03-27 | Piramed Limited | Pharmaceutical compounds |
| EP2402347A1 (en) * | 2006-04-26 | 2012-01-04 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
| AU2007243457B2 (en) * | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| WO2007122410A1 (en) | 2006-04-26 | 2007-11-01 | F.Hoffmann-La Roche Ag | Pyrimidine derivatives as pi3k inhibitors |
| US8697693B2 (en) | 2006-04-26 | 2014-04-15 | F. Hoffmann LaRoche AG | Pharmaceutical compounds |
| US20090029345A1 (en) * | 2006-08-01 | 2009-01-29 | Alan Russell | Modulating skeletal muscle |
| US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| US20110014212A1 (en) * | 2006-08-02 | 2011-01-20 | Aaron Hinken | Certain Chemical Entities, Compositions and Methods |
| US20100210645A1 (en) * | 2006-08-02 | 2010-08-19 | Cytokinetics, Inc. | Certain Chemical Entities, Compositions and Methods |
| US8293761B2 (en) | 2006-08-02 | 2012-10-23 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| US7956056B2 (en) | 2006-08-02 | 2011-06-07 | Cytokinetics, Inc. | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| US8716291B2 (en) | 2006-08-02 | 2014-05-06 | Cytokinetics, Inc. | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| US10766899B2 (en) | 2006-08-02 | 2020-09-08 | Cytokinetics, Incorporated | Methods for preparing substituted imidazo[4,5-b]pyrazines |
| US20100093741A1 (en) * | 2006-08-02 | 2010-04-15 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| EP2518074A1 (en) | 2006-12-07 | 2012-10-31 | F. Hoffmann-La Roche AG | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US20110071182A1 (en) * | 2007-02-07 | 2011-03-24 | Smithkline Beecham Corporation | Inhibitors of AKT Activity |
| US8410158B2 (en) | 2007-02-07 | 2013-04-02 | Glaxosmithkline Llc | Inhibitors of Akt activity |
| US8273782B2 (en) | 2007-02-07 | 2012-09-25 | Glaxosmithkline Llc | Inhibitors of Akt activity |
| US8946278B2 (en) | 2007-02-07 | 2015-02-03 | Glaxosmithkline Llc | Inhibitors of AkT activity |
| US20090209607A1 (en) * | 2007-02-07 | 2009-08-20 | Seefeld Mark A | Inhibitors of akt activity |
| US20100041726A1 (en) * | 2007-02-07 | 2010-02-18 | Smithkline Beecham Corporation | INHIBITORS OF Akt ACTIVITY |
| US7851484B2 (en) | 2007-03-30 | 2010-12-14 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US20080242695A1 (en) * | 2007-03-30 | 2008-10-02 | Morgan Bradley P | Certain Chemical Entities, Compositions, and Methods |
| US20100179124A1 (en) * | 2007-07-23 | 2010-07-15 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| US8350037B2 (en) | 2007-07-23 | 2013-01-08 | Ucb Pharma, S.A. | Thieno-pyridine derivatives as MEK inhibitors |
| WO2009013462A1 (en) * | 2007-07-23 | 2009-01-29 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| WO2009042607A1 (en) | 2007-09-24 | 2009-04-02 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| US8293735B2 (en) | 2007-10-26 | 2012-10-23 | F. Hoffmann-La Roche Ag | Thienopyrimidine derivatives as P13K inhibitors |
| US20110021496A1 (en) * | 2007-10-26 | 2011-01-27 | F. Hoffmann-La Roche Ag | Thienopyrimidine derivatives as p13k inhibitors |
| US8487101B2 (en) | 2008-01-21 | 2013-07-16 | Ucb Pharma S.A. | Thieno-pyridine derivatives as MEK inhibitors |
| US20110021558A1 (en) * | 2008-01-21 | 2011-01-27 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| US8637491B2 (en) | 2008-06-19 | 2014-01-28 | Ucb Pharma S.A. | Thieno-pyridine derivatives as MEK inhibitors |
| US20110172191A1 (en) * | 2008-06-19 | 2011-07-14 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| US9877968B2 (en) | 2008-08-11 | 2018-01-30 | Glaxosmithkline Llc | 6-amino-purin-8-one compounds |
| US10117873B2 (en) | 2008-08-11 | 2018-11-06 | Glaxosmithkline Llc | 6-amino-purin-8-one compounds |
| US8609711B2 (en) | 2009-01-30 | 2013-12-17 | Glaxosmithkline Llc | Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride |
| US20100197754A1 (en) * | 2009-01-30 | 2010-08-05 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| WO2010105008A2 (en) | 2009-03-12 | 2010-09-16 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| WO2010138589A1 (en) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| WO2011130654A1 (en) | 2010-04-16 | 2011-10-20 | Genentech, Inc. | Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy |
| US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
| WO2012088254A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
| US10272082B2 (en) | 2011-07-13 | 2019-04-30 | Cytokinetics, Inc. | Combination ALS therapy |
| US10112946B2 (en) | 2011-07-22 | 2018-10-30 | Glaxosmithkline Llc | Composition |
| US10022442B2 (en) | 2012-08-24 | 2018-07-17 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
| US9662336B2 (en) | 2012-08-24 | 2017-05-30 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
| US9555036B2 (en) | 2012-08-24 | 2017-01-31 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
| US9907847B2 (en) | 2012-11-20 | 2018-03-06 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| US9540383B2 (en) | 2012-11-20 | 2017-01-10 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| US9428512B2 (en) | 2012-11-20 | 2016-08-30 | Glaxosmithkline Llc | Compounds |
| WO2014130923A2 (en) | 2013-02-25 | 2014-08-28 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
| US9290496B2 (en) | 2013-11-21 | 2016-03-22 | Pfizer Inc. | Purine derivatives |
| US10709714B2 (en) | 2013-11-22 | 2020-07-14 | Clifton Life Sciences LLC | Gastrin antagonists for treatment and prevention of osteoporosis |
Also Published As
| Publication number | Publication date |
|---|---|
| US20010020030A1 (en) | 2001-09-06 |
| US6232320B1 (en) | 2001-05-15 |
| US6579882B2 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6232320B1 (en) | Cell adhesion-inhibiting antiinflammatory compounds | |
| EP1090009A2 (en) | Cell adhesion-inhibiting antinflammatory compounds | |
| EP1181296A1 (en) | Cell adhesion-inhibiting antiinflammatory compounds | |
| CA2390948A1 (en) | Cell adhesion-inhibiting antiinflammatory compounds | |
| CA2647208C (en) | Glucokinase activators | |
| ES2378704T3 (es) | Activadores de la glucocinasa | |
| US7902203B2 (en) | Anti-infective agents | |
| AU2006330924B2 (en) | Anti-viral compounds | |
| EP1971611B1 (en) | Anti-viral compounds | |
| AU2003270701B2 (en) | Antiinflammation agents | |
| ES2357230T3 (es) | Agentes antiinfecciosos. | |
| US20050075331A1 (en) | Anti-infective agents | |
| KR20090077051A (ko) | 3-아자-비시클로[3.1.0]헥산 유도체 | |
| JP2017505288A (ja) | Ｔｎｆ活性のモジュレーターとしての縮合二環式ヘテロ芳香族誘導体 | |
| AU2003291670A1 (en) | Anti-infective agents | |
| JP6469693B2 (ja) | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 | |
| CA2681695A1 (en) | 2-aminopyridine analogs as glucokinase activators | |
| EP3080133B1 (en) | Imidazothiazole derivatives as modulators of tnf activity | |
| RU2684635C1 (ru) | Производные тетрагидроимидазопиридина в качестве модуляторов активновти tnf | |
| JP5250649B2 (ja) | 抗感染薬 | |
| WO2009015897A1 (en) | Novel heterocyclic compounds as mglu5 antagonists | |
| MXPA00011994A (en) | Cell adhesion-inhibiting antinflammatory compounds | |
| CZ20004500A3 (cs) | Protizánětové sloučeniny inhibující buněčnou adhesi | |
| MXPA01012443A (es) | Compuestos antiinflamatorios inhibidores de adhesion de celula. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |